The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TST001 (a high affinity humanized anti-claudin18.2 monoclonal antibody) in combination with nivolumab plus capecitabine and oxaliplatin as first-line or with nivolumab as late-line treatment in locally advanced and metastatic gastric/gastroesophageal junction (G/GEJ) cancer: Design of cohorts from a phase I/IIa study (TST001-1002).
 
Weijian Guo
No Relationships to Disclose
 
Caroline Germa
No Relationships to Disclose
 
Chuan Qi
No Relationships to Disclose
 
Chunhua Qian
No Relationships to Disclose
 
Jenny Yao
No Relationships to Disclose
 
Jianming Wang
No Relationships to Disclose
 
Lijuan Zhang
No Relationships to Disclose
 
Xueming Qian
Employment - Transcenta
Leadership - Transcenta
Stock and Other Ownership Interests - Transcenta
 
Zhenzhong Xia
Employment - Ascentage Pharma Group; MabSpace Biosciences